How do we separate proven findings from marketing hype?
Kidney research is the prescription tier's showcase: the trials that changed kidney disease's trajectory (RAAS blockade, SGLT2 inhibitors, glucose and pressure control) are among medicine's best — and the supplement evidence base is thin, disease-specific, and population-cautionary. This field teaches the sharpest version of a lesson this library returns to: the organ that clears supplements is the organ where supplement evidence is scarcest and caution highest.
The field's prescription triumph and supplement caution teach together:
William Bowman's microscope work reveals the glomerular capsule and the filter's structure — the nephron's anatomy enters science.
In occupied Netherlands, sausage casing and orange-juice-cans build the first practical dialyzer — the sixteenth patient wakes from a uremic coma in 1945.
Joseph Murray transplants a kidney between identical twins in Boston — the first successful solid-organ transplant, Nobel-honored, made possible by immunologic luck and surgical courage.
The shunt makes chronic dialysis possible — and Seattle's citizen committee, forced to ration the machines, becomes the world's first bioethics committee.
Erythropoietin becomes the first blockbuster biotech drug — the kidney hormone manufactured for the anemia of kidney failure, transforming dialysis patients' lives.
A diabetes drug class proves kidney-protective in dedicated outcome trials (CREDENCE, DAPA-CKD) — the first therapy in decades to change CKD's trajectory, and the field's new benchmark.
POPULATION · 4,401 adults with type 2 diabetes and CKD, canagliflozin 100 mg daily
FINDING · The SGLT2 inhibitor reduced the composite of kidney failure, doubling of creatinine, or kidney death by ~30% — a dedicated kidney-outcome trial that changed the treatment paradigm.
LIMITATION · Diabetic CKD population; the class's benefit generalized in later trials (DAPA-CKD extended it to non-diabetic kidney disease), and amputation-signal debates from early data were not borne out — but prescription status and monitoring define real-world use.
POPULATION · 106 patients with IgA nephropathy, 12 g fish oil daily vs. placebo (omega-6), 2 years
FINDING · High-dose fish oil slowed the decline in kidney function versus placebo — 6% vs. 33% reaching end-stage or doubling creatinine in the original report.
LIMITATION · Small sample, debated effect size in subsequent trials and analyses (some replications positive, some null) — the honest verdict is a real but contested signal, graded moderate and disease-specific.
POPULATION · 199 first-time calcium stone formers, 5 years
FINDING · Urine volume >2 L/day halved stone recurrence (12.1% vs. 27.0%) — plain water, the simplest result in nephrology and the stones page's foundational evidence.
LIMITATION · Unblinded by nature, first-time formers — the effect is so large and mechanism so direct that the trial stands regardless.
POPULATION · US population screening cohorts (NHANES)
FINDING · ~15% of US adults have CKD by staging criteria, with ~90% unaware — the reserve-capacity organ failing silently, caught only by the labs this page's prevention chapter recommends.
LIMITATION · Staging criteria include stable mild reductions that not all would call disease — the awareness gap is the finding regardless of the definitional debate.
POPULATION · Cohorts with dietary-pattern tracking and kidney outcomes
FINDING · DASH/Mediterranean-pattern adherence associated with lower CKD incidence and slower decline — the whole-diet pattern outrunning single nutrients in the kidney data, as everywhere.
LIMITATION · Observational — healthy-pattern adherers differ in ways cohorts adjust imperfectly; the vascular-mechanism plausibility (the pattern IS cardio-protective, and the kidney is vascular) supports the direction.